Bioelectronics could lead to a new class of medicine

Jul 02, 2014

Imagine having tiny electronics implanted somewhere in your body that can regulate nerve signals and make symptoms of various disorders go away. That's the vision of the field of bioelectronic medicine—the emerging discipline that has made enough promising advances to draw a big investment by a pharmaceutical giant, according to an article in Chemical & Engineering News (C&EN), the weekly news magazine of the American Chemical Society.

Ann M. Thayer, a senior correspondent at C&EN, explains that much of the progress made in bioelectronic medicine has been driven by university research so far. But more than a year ago, the British drug company GlaxoSmithKline dove into the field and is now funding about 25 investigations exploring disease biology and neural signaling. They are betting that the budding discipline will lead to a whole new class of medicines for metabolic, immune-inflammatory, respiratory, cardiovascular and other disorders.

Others are also heavily invested in the future of bioelectronic science. A few start-ups are working toward clinical applications. The National Institutes of Health is also advancing neuroscience with its Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative. But scientists still have to work out some major puzzles before they can benefit patients. For one, they have to completely map out which nerves affect which organs and functions. Once that base is built, the field could be well poised to take off.

Explore further: On the road to improvement: EPA's troubled program on chemical hazards

More information: Shock Therapy, cen.acs.org/articles/92/i26/Shock-Therapy.html

add to favorites email to friend print save as pdf

Related Stories

Personalized medicine has finally arrived—or has it?

Feb 26, 2014

As the price for decoding a person's DNA keeps dropping, expectations for personalized medicine based on specific genetic profiling rise. But translating an individual's genetic data into finely tailored medical treatments ...

Pharma firms turn attention to hearing loss

Apr 09, 2014

Hearing loss affects 36 million Americans to some degree, often leaving them feeling isolated, but it has received little attention from the pharmaceutical industry—until now. Small firms have brought a handful of potential ...

Recommended for you

Science to the rescue of art

18 hours ago

Vincent van Gogh's "Sunflowers" are losing their yellow cheer and the unsettling apricot horizon in Edvard Munch's "The Scream" is turning a dull ivory.

Conjecture on the lateral growth of Type I collagen fibrils

Sep 12, 2014

Whatever the origin and condition of extraction of type I collagen fibrils, in vitro as well as in vivo, the radii of their circular circular cross sections stay distributed in a range going from 50 to 100 nm for the most ...

A dye with tunable optical characteristics

Sep 12, 2014

Researchers from RIKEN and the University of Tokyo have developed an organic dye molecule with tunable light-absorption and color characteristics. This development promises to open the door to the creation ...

User comments : 0